ArticleNPJ Parkinson's disease2021
Gait speed in clinical and daily living assessments in Parkinson's disease patients: performance versus capacity.
Article in NPJ Parkinson's disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 2 syntheses or guidelines pooled it, 90 citations in OpenAlex.
- Wearable Sensors in Gait Assessment for Parkinson Disease and Stroke in Real-World Environments: Systematic Review and Meta-Analysis.Journal of medical Internet research · 2026Pooled it
- Real-world gait study of Parkinson's disease using wearable sensors: a systematic review.Journal of neuroengineering and rehabilitation · 2026Pooled it
- Reliability and validity of the Roche PD Mobile Application for remote monitoring of early Parkinson's disease.Scientific reports · 2022Trial
- Detection of early-stage Parkinson's disease using wearable sensors at multiple body locations and convolutional neural networks.Scientific reports · 2026Article
- Multimodal machine learning mobility assessment in Parkinson's disease within supervised and unsupervised settings.Journal of neuroengineering and rehabilitation · 2026Article
- Sensor-Derived Parameters from Standardized Walking Tasks Can Support the Identification of Patients with Parkinson's Disease at Risk of Gait Deterioration.Bioengineering (Basel, Switzerland) · 2026Article
- Moving beyond the hospital: in-depth characterization of daily-life mobility in patients with atypical Parkinsonian disorders.NPJ Parkinson's disease · 2026Article
- Toward an understanding of real-world mobility in Parkinson's: insights from enhanced contextualisation using GPS-derived location and data-driven modeling of walking speed.Frontiers in aging neuroscience · 2026Article
- Single-task, dual-task, and community gait speeds of older adults in Singapore: their associations with frailty, cognition, and age-friendly cities.Innovation in aging · 2026Article
- Assessment of gait speed in older adults using a short-distance walking test with smartphone motion sensors and machine learning.Scientific reports · 2025Article
- Thigh-Worn Sensor for Measuring Initial and Final Contact During Gait in a Mobility Impaired Population: Validation Study.JMIR biomedical engineering · 2025Article
- A systematic review of real-world gait-related digital mobility outcomes in Parkinson's disease.NPJ digital medicine · 2025Article
- Multidisciplinary inpatient care for Parkinson's disease: a single-centre cohort study on improvements in gait, overall motor function, and quality of life.Neurological research and practice · 2025Article
- Characterizing Stair Ambulation Kinetics and the Effects of Dual Tasking in Parkinson's Disease.Journal of clinical medicine · 2025Article
- Evaluation of Free-Living Motor Symptoms in Patients With Parkinson Disease Through Smartwatches: Protocol for Defining Digital Biomarkers.JMIR research protocols · 2025Observational
- Influence of Gait Speed on Inter-Joint Coordination in People with and Without Parkinson's Disease.Biosensors · 2025Article
- Effects of virtual reality on spatiotemporal gait parameters and freezing of gait in Parkinson's disease.NPJ Parkinson's disease · 2025Article
- Systematic review of wearables assessing medication effect on motor function and symptoms in Parkinson's disease.NPJ Parkinson's disease · 2025Article
- How can patients shape digital medicine? A rapid review of patient and public involvement and engagement in the development of digital health technologies for neurological conditions.Expert review of pharmacoeconomics & outcomes research · 2025Review
- Association of real life postural transitions kinematics with fatigue in neurodegenerative and immune diseases.NPJ digital medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 3 countries.
Funding
Abstract
Gait speed often referred as the sixth vital sign is the most powerful biomarker of mobility. While a clinical setting allows the estimation of gait speed under controlled conditions that present functional capacity, gait speed in real-life conditions provides the actual performance of the patient. The goal of this study was to investigate objectively under what conditions during daily activities, patients perform as well as or better than in the clinic. To this end, we recruited 27 Parkinson's disease (PD) patients and measured their gait speed by inertial measurement units through several walking tests in the clinic as well as their daily activities at home. By fitting a bimodal Gaussian model to their gait speed distribution, we found that on average, patients had similar modes in the clinic and during daily activities. Furthermore, we observed that the number of medication doses taken throughout the day had a moderate correlation with the difference between clinic and home. Performing a cycle-by-cycle analysis on gait speed during the home assessment, overall only about 3% of the strides had equal or greater gait speeds than the patients' capacity in the clinic. These strides were during long walking bouts (>1 min) and happened before noon, around 26 min after medication intake, reaching their maximum occurrence probability 3 h after Levodopa intake. These results open the possibility of better control of medication intake in PD by considering both functional capacity and continuous monitoring of gait speed during real-life conditions.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.